192 related articles for article (PubMed ID: 31268728)
21. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
22. Mantle Cell Lymphoma: Which Patients Should We Transplant?
Gerson JN; Barta SK
Curr Hematol Malig Rep; 2019 Aug; 14(4):239-246. PubMed ID: 31218478
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of mantle cell lymphoma.
Hitz F; Bargetzi M; Cogliatti S; Lohri A; Taverna C; Renner C; Mey U
Swiss Med Wkly; 2013; 143():w13868. PubMed ID: 24226630
[TBL] [Abstract][Full Text] [Related]
24. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
[TBL] [Abstract][Full Text] [Related]
25. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
[TBL] [Abstract][Full Text] [Related]
26. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
28. Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma.
Takiar R; Phillips T
Curr Treat Options Oncol; 2021 Sep; 22(11):98. PubMed ID: 34524546
[TBL] [Abstract][Full Text] [Related]
29. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
[TBL] [Abstract][Full Text] [Related]
30. Clinical Management Updates in Mantle Cell Lymphoma.
Chen R; Sanchez J; Rosen ST
Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
[TBL] [Abstract][Full Text] [Related]
31. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
32. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in
Lew TE; Cliff ERS; Dickinson M; Tam CS; Seymour JF; Blombery P; Bajel A; Ritchie D; Khot A
Leuk Lymphoma; 2023; 64(11):1792-1800. PubMed ID: 37531077
[TBL] [Abstract][Full Text] [Related]
34. Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?
Broccoli A; Argnani L; Zinzani PL
Curr Hematol Malig Rep; 2021 Feb; 16(1):82-88. PubMed ID: 33646524
[TBL] [Abstract][Full Text] [Related]
35. Autologous transplantation and management of younger patients with mantle cell lymphoma.
Geisler CH
Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
[TBL] [Abstract][Full Text] [Related]
36. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
37. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Liu H; Johnson JL; Koval G; Malnassy G; Sher D; Damon LE; Hsi ED; Bucci DM; Linker CA; Cheson BD; Stock W
Haematologica; 2012 Apr; 97(4):579-85. PubMed ID: 22102709
[TBL] [Abstract][Full Text] [Related]
38. New strategies in the treatment of mantle cell lymphoma.
Deng C; Lee S; O'Connor OA
Clin Cancer Res; 2012 Jul; 18(13):3499-508. PubMed ID: 22700864
[TBL] [Abstract][Full Text] [Related]
39. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
40. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
